Virtual Reality Exposure Therapy in Psychosis

Conditions

Psychotic disorders with continuing social withdrawal Mental and Behavioural Disorders

Roos Pot-Kolder, Wim Veling, Chris Geraets, Joran Lokkerbol, Filip Smit et al. (8 authors)

Journal of Medical Internet Research2020-05-0479 citations

Effect of virtual reality exposure therapy on social participation in people with a psychotic disorder (VRETp): study protocol for a randomized controlled trial.

Pot-Kolder R, Veling W, Geraets C, van der Gaag M.

2016-01-1310 citations

10.1186/s13063-015-1140-0

Interventions

In both arms treatment as usual will be provided for the psychotic disorder for which the person sought help. In the first experimental arm there will be a maximum of 16 sessions (over three months) o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, either sex 2. Fullfilling diagnostic criteria for a psychotic disorder 3. Experiencing at least mild paranoia and/or social anxiety as measured with the Green et al. Paranoid Thought Scales (GPTS) and Social Interaction Anxiety Scale (SIAS)

Exclusion criteria

Exclusion criteria: 1. IQ under 70 2. Insufficient command of the Dutch language 3. Epilepsy

Design outcomes

Primary

Measure	Time frame
1. Experience Sampling Method (ESM) on social participation. 2. Objective social participation is expressed as the amount of time spend with other people and the type of company (for example family, friends, colleagues or strangers). 3. Subjective social participation is expressed as momentary paranoia, perceived social threat and event stress as experienced in social situations. All measures are measured at baseline, at end of treatment at 3 months, and at follow-up at 6 months.	—

Measure

Time frame

1. Experience Sampling Method (ESM) on social participation. 2. Objective social participation is expressed as the amount of time spend with other people and the type of company (for example family, friends, colleagues or strangers). 3. Subjective social participation is expressed as momentary paranoia, perceived social threat and event stress as experienced in social situations. All measures are measured at baseline, at end of treatment at 3 months, and at follow-up at 6 months.

—

Secondary

Measure	Time frame
1. Depression (BDI-II) 2. Stigmatisation and schemata (ISMI, BCSS) 3. Paranoia (GPTS) 4. Social interaction anxiety (SIAS) 5. Cognitive biases (DACOBS) 6. Safety behavior (Safety Behavior Questionnaire ? persecutory delusions) 7. Quality of life and cost-effectiveness (MANSA,TIC-P) 8. Presence and cyber sickness (SSQ, IPQ), measured at month 1 and at month 2 during treatment. 9. Psychosis (Positive and Negative symptom scales) 10. Social functioning (Social and Occupational Functioning Assessment Scales)	—

Measure

Time frame

1. Depression (BDI-II) 2. Stigmatisation and schemata (ISMI, BCSS) 3. Paranoia (GPTS) 4. Social interaction anxiety (SIAS) 5. Cognitive biases (DACOBS) 6. Safety behavior (Safety Behavior Questionnaire ? persecutory delusions) 7. Quality of life and cost-effectiveness (MANSA,TIC-P) 8. Presence and cyber sickness (SSQ, IPQ), measured at month 1 and at month 2 during treatment. 9. Psychosis (Positive and Negative symptom scales) 10. Social functioning (Social and Occupational Functioning Assessment Scales)

—

Countries

Netherlands

Outcome results

None listed